ArticleFrontiers in immunology2023
Co-infection of mice with SARS-CoV-2 and
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Review
- Prevalence of Long COVID inJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Bacterial extracellular vesicles modulate epithelial antiviral responses via macrophage-mediated immunomodulation.Cell communication and signaling : CCS · 2026Article
- Dissecting the effect of single- and co-infection of TB and COVID-19 pathogens on the sputum microbiome.Microbiology spectrum · 2026Article
- Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice.Journal of virology · 2026Article
- Crosstalk betweenFrontiers in immunology · 2026Article
- Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice.bioRxiv : the preprint server for biology · 2025Article
- Previously treated latent tuberculosis infection is associated with less severe acute COVID-19: a cohort study.BMJ open respiratory research · 2025Article
- Impact of the COVID-19 pandemic on the epidemiology and clinical course of tuberculosis: expected and paradoxical consequences.BMC infectious diseases · 2025Article
- Mycobacterium tuberculosis growth inhibition by peripheral blood mononuclear cells from household contacts is not affected by previous SARS-CoV-2 infection.Gates open research · 2025Article
- Unmasking the hidden impact of viruses on tuberculosis risk.Trends in immunology · 2024Review
- The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication.bioRxiv : the preprint server for biology · 2024Article
- Protective interplay:Frontiers in immunology · 2024Article
- Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2.Nature communications · 2023Article
- T Cell Response in Tuberculosis-Infected Patients Vaccinated against COVID-19.Microorganisms · 2023Article
- BCG mediated protection of the lung against experimental SARS-CoV-2 infection.Frontiers in immunology · 2023Review
- Tuberculosis and COVID-19 in the elderly: factors driving a higher burden of disease.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral co-infections have been implicated in worsening tuberculosis (TB) and during the COVID-19 pandemic, the global rate of TB-related deaths has increased for the first time in over a decade. We and others have previously shown that a resolved prior or concurrent influenza A virus infection in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.